Linagliptin

CAS 668270-12-0 28 API suppliersSmall Molecule

Overview

Linagliptin is a dipeptidyl peptidase 4 (DPP-4) inhibitor used as an oral hypoglycemic agent for the treatment of type 2 diabetes. It works by increasing the levels of incretin hormones, which inhibit glucagon release and increase insulin secretion.

API suppliers (28)

Suppliers of Linagliptin evidenced by a US FDA Type II Drug Master File or an EU Certificate of Suitability (CEP). Sources: FDA DMF list, EDQM certification database.

Where these suppliers are
India16China5Netherlands1

Country recorded for 22 of 28 suppliers.

14 of 28 hold a GMP certificate on record in the EU or UK registers

Showing 25 of 28 suppliers — see the full list in the app.

Patent & exclusivity (US)

Per the FDA Orange Book (9 approved US products), the latest listed US patent on Linagliptin expires 8 Dec 2037 and exclusivity 20 Dec 2026. Generic API sourcing typically opens up once these lapse.

Therapeutic areas

EndocrinologyMetabolic Disorders
Verified Supplier Partner

Do you supply Linagliptin? Get in front of buyers actively sourcing it.

We route real sourcing requests from pharma buyers to vetted, verified partners — qualified leads, not just a listing. Tell us what you make and we'll be in touch about becoming a Verified Supplier Partner.

No cost to enquire · we only reach out with a fit.

Ready to Accelerate Your
Discovery Workflow?

Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 7 days.